R Lowe1, M Ferrari1, M Nasim-Mohi1, A Jackson1,2, R Beecham1, K Veighey3, R Cusack1,2,4, D Richardson1, Mpw Grocott1,2,4, Dzh Levett1,2,4, A Dushianthan5,6,7. 1. General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England. 2. NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton / University of Southampton, Tremona Road, Southampton, SO16 6YD, England. 3. Renal Medicine, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England. 4. Faculty of Medicine, University of Southampton, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, England. 5. General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England. a.dushianthan@soton.ac.uk. 6. NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton / University of Southampton, Tremona Road, Southampton, SO16 6YD, England. a.dushianthan@soton.ac.uk. 7. Faculty of Medicine, University of Southampton, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, England. a.dushianthan@soton.ac.uk.
Abstract
BACKGROUND: Acute kidney injury (AKI) is a common manifestation among patients critically ill with SARS-CoV-2 infection (Coronavirus 2019) and is associated with significant morbidity and mortality. The pathophysiology of renal failure in this context is not fully understood, but likely to be multifactorial. The intensive care unit outcomes of patients following COVID-19 acute critical illness with associated AKI have not been fully explored. We conducted a cohort study to investigate the risk factors for acute kidney injury in patients admitted to and intensive care unit with COVID-19, its incidence and associated outcomes. METHODS: We reviewed the medical records of all patients admitted to our adult intensive care unit suffering from SARS-CoV-2 infection from 14th March 2020 until 12th May 2020. Acute kidney injury was defined using the Kidney Disease Improving Global Outcome (KDIGO) criteria. The outcome analysis was assessed up to date as 3rd of September 2020. RESULTS: A total of 81 patients admitted during this period. All patients had acute hypoxic respiratory failure and needed either noninvasive or invasive mechanical ventilatory support. Thirty-six patients (44%) had evidence of AKI (Stage I-33%, Stage II-22%, Renal Replacement Therapy (RRT)-44%). All patients with AKI stage III had RRT. Age, diabetes mellitus, immunosuppression, lymphopenia, high D-Dimer levels, increased APACHE II and SOFA scores, invasive mechanical ventilation and use of inotropic or vasopressor support were significantly associated with AKI. The peak AKI was at day 4 and mean duration of RRT was 12.5 days. The mortality was 25% for the AKI group compared to 6.7% in those without AKI. Among those received RRT and survived their illness, the renal function recovery is complete and back to baseline in all patients. CONCLUSION: Acute kidney injury and renal replacement therapy is common in critically ill patients presenting with COVID-19. It is associated with increased severity of illness on admission to ICU, increased mortality and prolonged ICU and hospital length of stay. Recovery of renal function was complete in all survived patients.
BACKGROUND:Acute kidney injury (AKI) is a common manifestation among patientscritically ill with SARS-CoV-2 infection (Coronavirus 2019) and is associated with significant morbidity and mortality. The pathophysiology of renal failure in this context is not fully understood, but likely to be multifactorial. The intensive care unit outcomes of patients following COVID-19 acute critical illness with associated AKI have not been fully explored. We conducted a cohort study to investigate the risk factors for acute kidney injury in patients admitted to and intensive care unit with COVID-19, its incidence and associated outcomes. METHODS: We reviewed the medical records of all patients admitted to our adult intensive care unit suffering from SARS-CoV-2 infection from 14th March 2020 until 12th May 2020. Acute kidney injury was defined using the Kidney Disease Improving Global Outcome (KDIGO) criteria. The outcome analysis was assessed up to date as 3rd of September 2020. RESULTS: A total of 81 patients admitted during this period. All patients had acute hypoxic respiratory failure and needed either noninvasive or invasive mechanical ventilatory support. Thirty-six patients (44%) had evidence of AKI (Stage I-33%, Stage II-22%, Renal Replacement Therapy (RRT)-44%). All patients with AKI stage III had RRT. Age, diabetes mellitus, immunosuppression, lymphopenia, high D-Dimer levels, increased APACHE II and SOFA scores, invasive mechanical ventilation and use of inotropic or vasopressor support were significantly associated with AKI. The peak AKI was at day 4 and mean duration of RRT was 12.5 days. The mortality was 25% for the AKI group compared to 6.7% in those without AKI. Among those received RRT and survived their illness, the renal function recovery is complete and back to baseline in all patients. CONCLUSION:Acute kidney injury and renal replacement therapy is common in critically illpatients presenting with COVID-19. It is associated with increased severity of illness on admission to ICU, increased mortality and prolonged ICU and hospital length of stay. Recovery of renal function was complete in all survived patients.
Entities:
Keywords:
Acute kidney injury; COVID-19; Intensive care
Authors: Evgeny V Fominskiy; Anna Mara Scandroglio; Giacomo Monti; Maria Grazia Calabrò; Giovanni Landoni; Antonio Dell'Acqua; Luigi Beretta; Elena Moizo; Alfredo Ravizza; Fabrizio Monaco; Corrado Campochiaro; Marina Pieri; Maria Luisa Azzolini; Giovanni Borghi; Martina Crivellari; Caterina Conte; Cristina Mattioli; Paolo Silvani; Milena Mucci; Stefano Turi; Stefano Tentori; Martina Baiardo Redaelli; Marianna Sartorelli; Piera Angelillo; Alessandro Belletti; Pasquale Nardelli; Francesco Giuseppe Nisi; Gabriele Valsecchi; Cristina Barberio; Fabio Ciceri; Ary Serpa Neto; Lorenzo Dagna; Rinaldo Bellomo; Alberto Zangrillo Journal: Blood Purif Date: 2020-07-13 Impact factor: 2.614
Authors: A Cau; M P Cheng; Terry Lee; A Levin; T C Lee; D C Vinh; F Lamontagne; J Singer; K R Walley; S Murthy; D Patrick; O Rewa; B Winston; J Marshall; J Boyd; J A Russell Journal: Can J Kidney Health Dis Date: 2021-10-30
Authors: Tahereh Sabaghian; Amir Behnam Kharazmi; Ali Ansari; Fatemeh Omidi; Seyyedeh Neda Kazemi; Bahareh Hajikhani; Roya Vaziri-Harami; Ardeshir Tajbakhsh; Sajjad Omidi; Sara Haddadi; Amir Hashem Shahidi Bonjar; Mohammad Javad Nasiri; Mehdi Mirsaeidi Journal: Front Med (Lausanne) Date: 2022-04-04